In one paragraphArticle in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
David Mauricio Cañedo-FigueroaLaboratorio de Virología Molecular, Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico.ORCID 0009-0005-8050-4587 Blanca Azucena Márquez-ReynaLaboratorio de Virología Molecular, Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico.ORCID 0009-0009-8790-2341 Alan Orlando Santos-MenaLaboratorio de Virología Molecular, Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico.ORCID 0000-0002-4853-3063 Daniela Nahomi Calderón-SandateLaboratorio de Virología Molecular, Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico.
Flor Itzel Lira-HernándezLaboratorio de Virología Molecular, Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico.
Julio E Castañeda-DelgadoInvestigadores por México (SECIHTI), Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico.ORCID 0000-0003-2124-2036 Ana Cristina García-HerreraLaboratorio de Virología Molecular, Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico.
Rosa María Del ÁngelDepartment of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico.ORCID 0000-0002-6785-2035 Moisés León-JuárezLaboratorio de Virología Perinatal y Diseño Molecular de Antígenos y Biomarcadores, Departamento de Inmunobioquimica, Instituto Nacional de Perinatología "Isidro Espinosa de los Reyes", Mexico City 11000, Mexico.ORCID 0000-0002-5726-5953 Marco Antonio Valdez-FloresFaculty of Medicine, Autonomous University of Sinaloa, Culiacan 80246, Mexico.
Gabriela López-AnguloFaculty of Medicine, Autonomous University of Sinaloa, Culiacan 80246, Mexico.
Claudia Desireé Norzagaray-ValenzuelaFaculty of Medicine, Autonomous University of Sinaloa, Culiacan 80246, Mexico.
Loranda Calderón-ZamoraFaculty of Medicine, Autonomous University of Sinaloa, Culiacan 80246, Mexico.ORCID 0000-0001-7423-2283 Evelin Cervantes-BobadillaFaculty of Medicine, Autonomous University of Sinaloa, Culiacan 80246, Mexico.
Juan Fidel Osuna-RamosLaboratorio de Virología y Diseño de Antivirales, Facultad de Medicina, Universidad Autónoma de Sinaloa (UAS), Culiacan 80246, Mexico.ORCID 0000-0001-8280-9812 Luis Adrián De Jesús-GonzálezLaboratorio de Virología Molecular, Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico.ORCID 0000-0003-1415-6260 Funding
FUNDACIÓN IMSS, A.C. Investigadores de Reciente Incorporación program from FUNDACIÓN IMSS, A.C. R-2024-785-073SECIHTI Ciencia Básica y de Frontera 2025, modalidad Individual program from SECIHTI (Project No. CBF-2025-I-1331)
6 · The paper itselfAbstract
The continuous emergence of SARS-CoV-2 variants highlights the need for novel antiviral agents with favorable safety profiles. Marine microalgae constitute a valuable source of bioactive compounds, including antiviral peptides. Building on previous
Indexed as
Antiviral AgentsCOVID-19 Drug TreatmentDiatomsMicroalgaePeptidesSARS-CoV-2A549 CellsCell SurvivalHumansMolecular WeightAntiviral AgentsPeptidesantiviral peptidesin vitro antiviral activitymarine microalgaeOmicron variantpeptide fractionsPhaeodactylum tricornutumSARS-CoV-2
Identifiers
PMID42042197
PMCPMC13118173
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390